E-LIB Suche - Ergebnisse für: Wolff-Holz, Elena

1

Do the Outcomes of Clinical Efficacy Trials Matter in Regul..:

Kirsch-Stefan, Nadine ; Guillen, Elena ; Ekman, Niklas...
BioDrugs. 37 (2023) 6 - p. 855-871 , 2023

Link: https://doi.org/10.1007/..

2

Regulatory Evaluation of Biosimilars: Refinement of Princip..:

Kurki, Pekka ; Kang, Hye-Na ; Ekman, Niklas...
BioDrugs. 36 (2022) 3 - p. 359-371 , 2022

Link: https://doi.org/10.1007/..

3

Safety, Immunogenicity and Interchangeability of Biosimilar..:

Kurki, Pekka ; Barry, Sean ; Bourges, Ingrid..
Drugs. 81 (2021) 16 - p. 1881-1896 , 2021

Link: https://doi.org/10.1007/..

4

Biosimilars in der EU: Bestandsaufnahme und neue Herausford..:

Wolff-Holz, Elena ; Weise, Martina
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 63 (2020) 11 - p. 1365-1372 , 2020

Link: https://doi.org/10.1007/..

5

Biosimilar medicines: Why the science matters:

Gonzalez-Quevedo, Rosa ; Wolff-Holz, Elena ; Carr, Melanie.
Health Policy and Technology. 9 (2020) 2 - p. 129-133 , 2020

Link: https://doi.org/10.1016/..

6

Evolution of the EU Biosimilar Framework: Past and Future:

Wolff-Holz, Elena ; Tiitso, Klara ; Vleminckx, Camille.
BioDrugs. 33 (2019) 6 - p. 621-634 , 2019

Link: https://doi.org/10.1007/..

7

Preparing for the incoming wave of biosimilars in oncology:

Wolff-Holz, Elena ; Garcia Burgos, Juan ; Giuliani, Rosa...
ESMO Open. 3 (2018) 6 - p. e000420 , 2018

Link: https://doi.org/10.1136/..

8

Interchangeability of Biosimilars: A European Perspective:

Kurki, Pekka ; van Aerts, Leon ; Wolff-Holz, Elena...
BioDrugs. 31 (2017) 2 - p. 83-91 , 2017

Link: https://doi.org/10.1007/..

9

Do the Outcomes of Clinical Efficacy Trials Matter in Regul..:

Kirsch-Stefan, Nadine ; Guillen, Elena ; Ekman, Niklas...
https://repository.publisso.de/resource/frl:6472875. , 2023

Link: https://repository.publi..

10

Do the Outcomes of Clinical Efficacy Trials Matter in Regul..:

Kirsch-Stefan, Nadine ; Guillen, Elena ; Ekman, Niklas...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581956/. , 2023

Link: http://www.ncbi.nlm.nih...

11

Regulatory Evaluation of Biosimilars : Refinement of Princi..:

Kurki, Pekka ; Kang, Hye Na ; Ekman, Niklas...
10.1007/s40259-022-00533-x. , 2023

Link: http://hdl.handle.net/10..

12

A Data Driven Approach to Support Tailored Clinical Program..:

Guillen Benitez, Elena ; Ekman, Niklas ; Barry, Sean..
Clinical Pharmacology & Therapeutics;113(1). , 2023

Link: https://hdl.handle.net/1..

13

Safety, Immunogenicity and Interchangeability of Biosimilar..:

Kurki, Pekka ; Barry, Sean ; Bourges, Ingrid..
10.1007/s40265-021-01601-2. , 2022

Link: http://hdl.handle.net/10..

14

Regulatory Evaluation of Biosimilars: Refinement of Princip..:

Kurki, Pekka ; Kang, Hye-Na ; Ekman, Niklas...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148871/. , 2022

Link: http://www.ncbi.nlm.nih...

15

Safety, Immunogenicity and Interchangeability of Biosimilar..:

Kurki, Pekka ; Barry, Sean ; Bourges, Ingrid..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578115/. , 2021

Link: http://www.ncbi.nlm.nih...